In preclinical studies, trastuzumab-resistant, lapatinib-resistant, and afatinib-resistant GC cells were found to have a significant increase in the basal levels of phosphorylated Src and ERK1/2 when compared to sensitive GC cells [114,115,128]. The gene discussed is SRC; the disease is gastric cancer.